A decade into their quest to conduct successful Phase III clinical trials in the US, Chinese developers of innovative drugs seemed to lose steam in 2022 - but are still clinging to new hope over the upcoming years.
10 Years On, Chinese Biopharma Firms Making US Inroads: A Snapshot
Seeking Major Market For Innovative Assets
From 2013 to November 2022, Chinese pharma companies as a single sponsor started a total of 35 international Phase III clinical studies for innovative drugs in the US, indicating a continuing push by the biopharma sector in the country to leverage increasing innovation to access this huge and lucrative market. Led by BeiGene, 20 firms have placed their bets on such studies and some are planning similar new moves despite an ongoing downturn in industry funding, this infographic analysis shows.
